Ionis Pharmaceuticals Inc (IONS)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$75.00

Buy

$82.01

arrow-up$1.68 (+2.12%)

Prices updated at 13 Dec 2025, 00:56 EST

Prices minimum 15 mins delay

Prices in USD

Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Joseph Loscalzo, M.D.,PhD

CEO

Dr. Brett P. Monia, PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

927

Head office

2855 Gazelle Court

Carlsbad

United States

92010

+1 760 931-9200

WWalke@ionisph.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Richard S. Geary,PhD Executive Vice President and Chief Development Officer	0.59m
Dr. Holly Kordasiewicz, PhD Senior Vice President, Neurology	-
Ms. B. Lynne Parshall, Esq.,J.D. Director	0.09m
Mr. Joseph H. Wender Lead Independent Director	0.15m
Mr. Joseph Klein, III Independent Director	0.09m
Dr. Joseph Loscalzo, M.D.,PhD Chairman of the Board	0.12m
Dr. C. Frank Bennett,PhD Executive Vice President and Chief Scientific Officer	-
Ms. Joan E. Herman Independent Director	0.09m
Dr. Spencer R. Berthelsen,M.D. Independent Director	0.10m
Dr. Michael Hayden, PhD Independent Director	0.08m
Dr. Brett P. Monia, PhD Chief Executive Officer and Director	1.01m
Ms. Elizabeth L. Hougen Executive Vice President, Finance, Principal Accounting Officer and Chief Financial Officer	0.70m
Mr. Patrick R. O'Neil, Esq. Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary	0.59m
Mr. Michael J. Yang Independent Director	0.07m
Ms. Allene M. Diaz Independent Director	0.08m
Mr. Kyle Jenne Executive Vice President and Chief Global Product Strategy Officer	0.45m
Mr. Eric E. Swayze, PhD Executive Vice President, Research	-
Mr. Joseph T. Baroldi Executive Vice President and Chief Business Officer	-
Mr. Eugene Schneider Executive Vice President and Chief Clinical Development and Operations Officer	-
Mr. Brian Birchler Executive Vice President, Corporate and Development Operations	-
Ms. Shannon L. Devers Executive Vice President and Chief Human Resources Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
FMR Inc	23,689,038
Fidelity Management and Research Company	23,689,038
Vanguard Group Inc	16,714,846
T. Rowe Price Investment Management,Inc.	13,156,929
Capital World Investors	12,722,728

Director dealings

Date chevron-l-regular chevron-r-regular	Action
23 Dec 2024	-
23 Dec 2024	-
12 Nov 2024	-
12 Nov 2024	-
12 Nov 2024	-
15 Oct 2024	-
15 Oct 2024	-
16 Oct 2024	-
15 Oct 2024	-
29 Sep 2024	-
30 Aug 2024	-
30 Aug 2024	-
30 Aug 2024	-
30 Aug 2024	-
30 Aug 2024	-
30 Aug 2024	-
28 Aug 2024	-
29 Aug 2024	-
05 Aug 2024	-
16 Jul 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.